A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
Public ClinicalTrials.gov record NCT03395080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Study identification
- NCT ID
- NCT03395080
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Interventions
- 300mg DKN-01 Drug
- 600mg DKN-01 Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 4, 2018
- Primary completion
- Sep 8, 2020
- Completion
- Jan 26, 2021
- Last update posted
- Jul 31, 2025
2018 – 2021
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| HonorHealth | Scottsdale | Arizona | 85258 | — |
| Florida Cancer Specialists & Research Institute | West Palm Beach | Florida | 33401 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| HCA Midwest Health System Clinical Research | Kansas City | Missouri | 64132 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University Wexner Medical Center | Hilliard | Ohio | 43026 | — |
| Stephenson Cancer Center - University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| The University of Tennessee West Cancer Center | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22903 | — |
| University of Wisconsin | Madison | Wisconsin | 53715 | — |
| Froedtert and Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03395080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03395080 live on ClinicalTrials.gov.